Avalere Health has announced the appointment of Corrina Safeio as its new president, global marketing and executive vice ...

GSK’s “ultra-long-acting” biologic depemokimab has demonstrated a significant reduction in severe asthma exacerbations over ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as an add-on maintenance treatment for chronic obstructive pulmonary ...

Gilead Sciences and artificial intelligence (AI)-focused Genesis Therapeutics have entered into a collaboration aimed at developing small molecule therapies across multiple targets. The partners will ...

Pfizer and Valneva have shared promising immune response and safety results from a mid-stage study of their Lyme disease vaccine candidate. The phase 2 VLA15-221 trial randomised healthy participants ...

Pfizer’s Elrexfio (elranatamab) has been accepted by the Scottish Medicines Consortium (SMC) for use as a monotherapy in adults with relapsed and refractory multiple myeloma. The BCMA-directed ...

The regulator’s decision expands the drug’s indication to cover all patients who are at risk of disease progression The US Food and Drug Administration (FDA) has granted full approval to Travere ...

Merck & Co – known as MSD outside the US and Canada – and Daiichi Sankyo’s investigational antibody-drug conjugate (ADC) ifinatamab deruxtecan has demonstrated promising results in a mid-stage lung ...

Eli Lilly and HAYA Therapeutics have entered into a multi-year agreement worth up $1bn to discover regulatory genome targets for obesity and related metabolic conditions. The collaboration centres ...

Regeneron Pharmaceuticals has shared positive five-years results from a late-stage study of Libtayo (cemiplimab) in advanced lung cancer. The phase 3 EMPOWER-Lung 1 trial compared the monoclonal ...

Eli Lilly and artificial intelligence (AI)-focused Genetic Leap have entered into a research collaboration worth up to $409m to develop genetic medicines. The partnership will see the companies use ...